Propanc Biopharma Plans Phase 1b PRP Trial in Up to 50 Patients
Propanc Biopharma plans a Phase 1b PRP trial involving up to 50 advanced cancer patients.
Related stories
Indonesia central bank governor calls MSCI warning a short-term shock
Destry Damayanti said MSCI’s recent warning about a possible downgrade of Indonesian equities would be only a short-term shock.
L impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
MQ Technology Q2 FY27 Net Loss Widens to RM 8.25 Million
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
Haleon Cuts 2026 Organic Revenue Growth Guidance to Around 2.5%
Haleon lowered its 2026 organic revenue growth outlook to around 2.5%, from 3% to 5%. Third-quarter organic revenue growth was 2.6%, below the company’s expectations, with price up
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
Remegen Q3 Net Profit at 610.9 Million Yuan
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
MQ Technology Reports Quarterly Attributable Loss of 8.2 Million RGT
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
Ningbo Tuopu Q3 Net Profit Falls 4.8% Year Over Year
M impact | EQUITY | Oct 29, 2026, 09:36 AM UTC